WO2024218296 - COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS
National phase entry is expected:
Publication Number
WO/2024/218296
Publication Date
24.10.2024
International Application No.
PCT/EP2024/060716
International Filing Date
19.04.2024
Title **
[English]
COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS
[French]
TRAITEMENTS COMBINÉS COMPRENANT L'ADMINISTRATION D'INHIBITEURS DE KINASE 2 À RÉPÉTITION RICHE EN LEUCINE (LRRK2)
Applicants **
H. LUNDBECK A/S
VERNALIS (R&D) LIMITED
Inventors
JENSEN, Thomas
ANDERSEN, Thomas
JESSING, Mikkel
YU, Wanwan
DIAZ, David Rodriguez
NIELSEN, Jacob
JONES, Christopher Richard
JACOBSEN, Mikkel Fog
Priority Data
23168881.3
20.04.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3781 | |
| EPO | Filing, Examination, Granting | 17219 | |
| Japan | Filing, Examination, Granting | 2393 | |
| South Korea | Filing, Examination, Granting | 2435 | |
| USA | Filing, Examination, Granting | 6090 |
Total:
31,918
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention is directed to combination treatment comprising administration of a first compound of formula I which is a Leucine-rich repeat kinase 2 (LRRK2) inhibitor and a second compound, which compound is useful in the treatment of synucleinopathies, such as Parkinson's disease; wherein formula (I) is.[French]
La présente invention concerne un traitement combiné comprenant l'administration d'un premier composé de formule I qui est un inhibiteur de la kinase 2 à répétition riche en leucine (LRRK2) et d'un second composé, lequel composé est utile dans le traitement de synucléinopathies, telles que la maladie de Parkinson ; la formule (I) étant .